Nureca Ltd. (NURECA) AI Stock Analysis

• Market Cap: ₹2.84B
• Dividend Yield: N/A
• Average Volume (3M): 9.27K
• Price to Earnings (P/E): 69.9
• Beta (1Y): 0.89
• Revenue Growth: 43.30%
• EPS Growth: N/A
• Country: IN
• Employees: 138
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 3.63
• Shares Outstanding: 10,000,175
• 10 Day Avg. Volume: 526
• 30 Day Avg. Volume: 9,266
• PEG Ratio: -1.76
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -9.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: ₹307.00 ▲(6.89% Upside)

Nureca Ltd.'s overall stock score is primarily influenced by its challenging financial performance, marked by negative profitability and cash flow issues. While technical analysis shows positive momentum, the high P/E ratio suggests overvaluation. The absence of earnings call data and corporate events limits additional insights.

Positive Factors

Strong Equity Position

A strong equity position with low leverage enhances financial stability and provides a buffer against economic downturns, supporting long-term growth.

Revenue Growth

Significant revenue growth indicates strong market demand and effective sales strategies, contributing to the company's potential for future expansion.

Product Innovation

Continuous product innovation helps maintain competitive advantage and customer loyalty, essential for sustaining long-term revenue streams.

Negative Factors

Negative Profitability

Negative profitability can hinder reinvestment in growth initiatives and affect the company's ability to withstand competitive pressures over time.

Cash Flow Issues

Negative cash flow impacts the company's ability to fund operations and invest in future growth, posing a risk to financial health and sustainability.

Operational Inefficiencies

Operational inefficiencies can lead to increased costs and reduced margins, affecting the company's competitiveness and long-term profitability.

Nureca Ltd. Business Overview & Revenue Model

Company Description

Nureca Ltd. (NURECA) is a technology-driven company focused on the health and wellness sector. It specializes in providing a diverse range of innovative healthcare products, including medical devices, fitness equipment, and digital health solutions. The company's mission is to enhance the quality of life for its customers by offering advanced products that cater to various health needs, targeting both individual consumers and healthcare professionals.

How the Company Makes Money

Nureca generates revenue primarily through the sale of its healthcare and wellness products, which are marketed through various channels, including e-commerce platforms, retail partnerships, and direct-to-consumer sales. The company employs a multi-channel distribution strategy to reach a broader customer base and increase sales volume. Additionally, Nureca may explore revenue opportunities through strategic partnerships with healthcare providers and institutions, which can facilitate bulk purchases and enhance brand visibility. The company's focus on product innovation and customer engagement also plays a critical role in driving repeat sales and fostering brand loyalty, contributing significantly to its overall earnings.

Nureca Ltd. Financial Statement Overview

Summary

Nureca Ltd. faces mixed financial health with strong equity positions and controlled debt levels. However, declining revenues, negative profitability, and cash flow challenges present significant hurdles. Improvements in operational efficiency and cash management are needed.

Income Statement

Nureca Ltd. has shown volatile revenue trends with a decline in revenue from 2022 to 2025. The gross profit margin remains moderate at approximately 38% in 2025, but net profitability is a concern with fluctuating net income, swinging to losses in recent periods. The EBIT margin is negative, indicating operational challenges. EBITDA shows improvement in 2025 compared to previous years, but overall performance remains inconsistent.

Balance Sheet

Nureca Ltd.'s balance sheet showcases strong equity with a high equity ratio of around 92% in 2025, indicating low leverage. The debt-to-equity ratio is favorable, suggesting prudent debt management. However, declining total assets over recent periods may signal underlying issues in asset management or utilization.

Cash Flow

The cash flow analysis reveals a challenging financial position with negative free cash flow growth and operating cash flow. The free cash flow to net income ratio is unfavorable, highlighting inefficiencies in converting income to cash. Despite some capital investment, liquidity remains a concern.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.24B	1.10B	919.28M	1.11B	2.56B	2.13B
Gross Profit	413.64M	231.33M	311.42M	355.94M	1.23B	1.14B
EBITDA	34.81M	48.95M	2.41M	-79.04M	632.04M	642.33M
Net Income	-30.00K	8.46M	-17.94M	-82.50M	449.60M	463.74M
Balance Sheet
Total Assets	0.00	2.10B	2.05B	2.07B	2.19B	1.86B
Cash, Cash Equivalents and Short-Term Investments	1.23B	736.29M	1.44B	1.02B	927.10M	1.27B
Total Debt	0.00	49.66M	25.16M	33.27M	44.05M	38.85M
Total Liabilities	-1.94B	156.91M	120.54M	116.97M	159.32M	226.54M
Stockholders Equity	1.94B	1.94B	1.93B	1.95B	2.03B	1.63B
Cash Flow
Free Cash Flow	0.00	-234.06M	-37.98M	98.31M	-46.00M	341.40M
Operating Cash Flow	0.00	-190.83M	-27.12M	102.27M	13.99M	348.67M
Investing Cash Flow	0.00	84.39M	175.76M	-164.56M	-30.89M	-1.10B
Financing Cash Flow	0.00	-1.69M	-13.03M	-15.07M	-73.02M	923.39M

Nureca Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 287.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NURECA, the sentiment is Positive. The current price of 287.2 is below the 20-day moving average (MA) of 289.62, above the 50-day MA of 278.29, and above the 200-day MA of 255.84, indicating a neutral trend. The MACD of 3.26 indicates Positive momentum. The RSI at 49.35 is Neutral, neither overbought nor oversold. The STOCH value of 28.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NURECA.

Nureca Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	65 Neutral	₹34.57B	23.44	―	1.70%	14.11%	7.47%
NURECA	57 Neutral	₹2.84B	69.93	―	―	43.30%	―
MOREPENLAB	57 Neutral	₹22.37B	22.68	―	0.49%	-0.29%	-29.04%
SOLARA	55 Neutral	₹20.70B	424.32	―	―	-4.18%	―
ZOTA	52 Neutral	₹46.99B	-72.14	―	0.06%	82.58%	-63.05%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	40 Neutral	₹22.19B	-19.79	―	0.08%	-2.81%	-444.69%

Nureca Ltd. Corporate Events

Nureca Ltd. Dissolves Wholly Owned Subsidiary to Streamline Operations

Nureca Ltd. announced the dissolution of its wholly owned subsidiary, Nureca Healthcare Private Limited, effective December 3, 2025. This strategic move is part of the company’s ongoing efforts to streamline operations and could potentially impact its market positioning by allowing it to focus more on its core business areas.

Nureca Limited Announces Share Buyback to Enhance Shareholder Value

Nureca Limited’s Board of Directors has approved a buyback of 580,000 fully paid equity shares at a price of Rs. 330 per share, totaling Rs. 19.14 crore. This buyback, representing approximately 9.8% of the company’s paid-up equity share capital and free reserves, is set to exclude promoters and will be conducted through a tender offer. The move is expected to enhance shareholder value and reflects the company’s robust financial position.

Nureca Ltd. Announces Rs. 19.14 Crore Share Buyback

Nureca Ltd. has announced a buyback of 580,000 fully paid equity shares at a price of Rs. 330 per share, totaling Rs. 19.14 crore. This strategic move, excluding promoters and their group, aims to optimize the capital structure and enhance shareholder value, reflecting the company’s commitment to its investors.

Nureca Limited Announces Share Buyback to Optimize Capital Structure

Nureca Limited has announced a buyback of 580,000 equity shares at a price of Rs. 330 per share, totaling Rs. 19.14 crore. This buyback, representing approximately 9.8% of the company’s equity share capital and free reserves, is set to exclude promoters and will be executed through a tender offer. The move is expected to optimize the capital structure and potentially enhance shareholder value, with Mefcom Capital Markets Limited appointed as the manager to the buyback.

Nureca Ltd. Announces Trading Window Closure Ahead of Share Buyback

Nureca Ltd. announced the closure of its trading window from November 26 to December 2, 2025, in compliance with SEBI regulations, due to a scheduled board meeting on November 28, 2025, for the buyback of shares. This move is part of the company’s efforts to adhere to insider trading regulations, impacting designated persons and their immediate relatives by prohibiting them from dealing in the company’s equity shares during this period.

Nureca Ltd. Postpones Board Meeting Amid Director Unavailability

Nureca Ltd. announced the postponement of its Board Meeting originally scheduled for November 10, 2025, due to the unavailability of a majority of its Independent Directors. The meeting was intended to discuss a proposal for the buyback of equity shares. As a result, the trading window for directors and designated officers will open on November 10, 2025, as per the company’s Code of Conduct for the prevention of insider trading.

Nureca Ltd. Releases Q2 and Half-Year Financial Results

Nureca Ltd. announced the approval of its unaudited standalone and consolidated financial results for the second quarter and half-year ending September 30, 2025. The financial results, which include the cash flow statement and statement of assets and liabilities, were reviewed by the Board of Directors in a meeting held on October 16, 2025. The announcement is significant for stakeholders as it provides insights into the company’s financial health and operational performance, maintaining transparency and compliance with regulatory requirements.

Nureca Limited Announces CFO Resignation

Nureca Limited announced the resignation of its Chief Financial Officer, Naresh Gupta, effective January 9, 2026. This change in leadership is part of the company’s ongoing adjustments and is not attributed to any material reasons beyond those stated in Gupta’s resignation letter. The transition is expected to be managed smoothly, ensuring minimal disruption to Nureca’s operations and strategic objectives.